Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.34 +3.03%
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Join SI Premium – FREE
Leerink Partners raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $46.00 (from $36.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades Keyence Corp. (6861:JP) (KYCCF) to Buy
- Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) PT Raised to IDR4,050 at CLSA
- Ito En Ltd (2593:JP) PT Raised to JPY3,300 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
